Ex parte EISENHARDT et al. - Page 9




              Appeal No. 1999-1229                                                                                      
              Application 08/543,975                                                                                    
              examiner has engaged in impermissible hindsight in making her determination of                            
              obviousness.  In re Gorman, 933 F.2d 982, 987, 18 USPQ2d 1855, 1888 (Fed. Cir.                            
              1991)(“It is impermissible, however, simply  to engage in a hindsight reconstruction of the               
              claimed invention, using the applicant’s structure as a template and selecting elements from              
              references to fill the gaps”); Interconnect Planning Corp. v. Feil, 774 F.2d 1132, 1138, 227              
              USPQ 543, 547 (Fed. Cir. 1985); W.L. Gore & Assocs. v. Garlock, Inc., 721 F.2d 1540,                      
              1553, 220 USPQ 303, 312-313 (Fed. Cir. 1983), cert. denied, 469 U.S. 851 (1984)(“To                       
              imbue one of ordinary skill in the art with knowledge of the invention in suit, when no prior art         
              reference or references of record convey or suggest that knowledge, is to fall victim to the              
              insidious effect of a hindsight syndrome wherein that which only the inventor taught is used              
              against its teacher”).                                                                                    
                     Third, it appears that the examiner has not fully appreciated the actual subject matter            
              encompassed by the claims.  We point out that the most generic claim before us is directed                
              to a solid, orally administrable composition having a therapeutically effective amount of two             
              different lactases, having two different optimum pH ranges, and a solid pharmaceutically                  
              acceptable carrier.  See claim 1, above.  The more specific claims are directed to solid,                 
              orally-administrable compositions comprising specific lactases, specific dosages, specific                
              pH ranges, enteric coatings, etc.  The examiner fails to address (i) any particular claim, or             
              (ii) the actual limitations in any of the claims.  Rather, we find that the rejection consists only       
              of broad, sweeping generalizations as to why the claimed subject matter would have been                   


                                                           9                                                            





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  Next 

Last modified: November 3, 2007